Therapeutic options for rheumatoid arthritis

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Background: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder primarily targeting the synovium. Unchecked disease activity is associated with significant morbidity and an increased mortality. Recent advances in the understanding of the pathogenesis of RA and the capability of biologically engineered treatments for RA have expanded the armamentarium of antirheumatic agents. Methods: A systematic literature review was conducted through PubMed. Results/conclusions: At present, a common strategy for the treatment of RA uses methotrexate either as monotherapy or in combination with a variety of conventional and/or biologic disease-modifying antirheumatic drugs (DMARDs), with the goal of inducing remission of active disease. The choice of which agent(s) to use is based upon patient-specific criteria (activity of disease, comorbidities, patient preferences, costs etc.). Emerging therapies that target specific cytokines and growth factors in the inflammatory cascade of RA offer a potent new means of modifying disease activity, but many questions regarding their use remain unanswered.

Original languageEnglish (US)
Pages (from-to)2095-2106
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume10
Issue number13
DOIs
StatePublished - Sep 1 2009

Fingerprint

Rheumatoid Arthritis
Antirheumatic Agents
Therapeutics
Synovial Membrane
Patient Preference
PubMed
Methotrexate
Comorbidity
Intercellular Signaling Peptides and Proteins
Cytokines
Morbidity
Costs and Cost Analysis
Mortality

Keywords

  • Abatacept
  • Adalimumab
  • Anakinra
  • Azathioprine
  • DMARDS
  • Etanercept
  • Hydroxychloroquine
  • Infliximab
  • Leflunomide
  • Methotrexate
  • Rheumatoid arthritis
  • Rituximab
  • Sulfasalazine
  • Tumor necrosis factor-alpha (TNF-α) inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Therapeutic options for rheumatoid arthritis. / Feely, Michael G.; Erickson, Alan R; O'Dell, James Robert.

In: Expert Opinion on Pharmacotherapy, Vol. 10, No. 13, 01.09.2009, p. 2095-2106.

Research output: Contribution to journalReview article

@article{fd2be7f8ae5c4f4eaa4515b187ebfc90,
title = "Therapeutic options for rheumatoid arthritis",
abstract = "Background: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder primarily targeting the synovium. Unchecked disease activity is associated with significant morbidity and an increased mortality. Recent advances in the understanding of the pathogenesis of RA and the capability of biologically engineered treatments for RA have expanded the armamentarium of antirheumatic agents. Methods: A systematic literature review was conducted through PubMed. Results/conclusions: At present, a common strategy for the treatment of RA uses methotrexate either as monotherapy or in combination with a variety of conventional and/or biologic disease-modifying antirheumatic drugs (DMARDs), with the goal of inducing remission of active disease. The choice of which agent(s) to use is based upon patient-specific criteria (activity of disease, comorbidities, patient preferences, costs etc.). Emerging therapies that target specific cytokines and growth factors in the inflammatory cascade of RA offer a potent new means of modifying disease activity, but many questions regarding their use remain unanswered.",
keywords = "Abatacept, Adalimumab, Anakinra, Azathioprine, DMARDS, Etanercept, Hydroxychloroquine, Infliximab, Leflunomide, Methotrexate, Rheumatoid arthritis, Rituximab, Sulfasalazine, Tumor necrosis factor-alpha (TNF-α) inhibitors",
author = "Feely, {Michael G.} and Erickson, {Alan R} and O'Dell, {James Robert}",
year = "2009",
month = "9",
day = "1",
doi = "10.1517/14656560903071043",
language = "English (US)",
volume = "10",
pages = "2095--2106",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "13",

}

TY - JOUR

T1 - Therapeutic options for rheumatoid arthritis

AU - Feely, Michael G.

AU - Erickson, Alan R

AU - O'Dell, James Robert

PY - 2009/9/1

Y1 - 2009/9/1

N2 - Background: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder primarily targeting the synovium. Unchecked disease activity is associated with significant morbidity and an increased mortality. Recent advances in the understanding of the pathogenesis of RA and the capability of biologically engineered treatments for RA have expanded the armamentarium of antirheumatic agents. Methods: A systematic literature review was conducted through PubMed. Results/conclusions: At present, a common strategy for the treatment of RA uses methotrexate either as monotherapy or in combination with a variety of conventional and/or biologic disease-modifying antirheumatic drugs (DMARDs), with the goal of inducing remission of active disease. The choice of which agent(s) to use is based upon patient-specific criteria (activity of disease, comorbidities, patient preferences, costs etc.). Emerging therapies that target specific cytokines and growth factors in the inflammatory cascade of RA offer a potent new means of modifying disease activity, but many questions regarding their use remain unanswered.

AB - Background: Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder primarily targeting the synovium. Unchecked disease activity is associated with significant morbidity and an increased mortality. Recent advances in the understanding of the pathogenesis of RA and the capability of biologically engineered treatments for RA have expanded the armamentarium of antirheumatic agents. Methods: A systematic literature review was conducted through PubMed. Results/conclusions: At present, a common strategy for the treatment of RA uses methotrexate either as monotherapy or in combination with a variety of conventional and/or biologic disease-modifying antirheumatic drugs (DMARDs), with the goal of inducing remission of active disease. The choice of which agent(s) to use is based upon patient-specific criteria (activity of disease, comorbidities, patient preferences, costs etc.). Emerging therapies that target specific cytokines and growth factors in the inflammatory cascade of RA offer a potent new means of modifying disease activity, but many questions regarding their use remain unanswered.

KW - Abatacept

KW - Adalimumab

KW - Anakinra

KW - Azathioprine

KW - DMARDS

KW - Etanercept

KW - Hydroxychloroquine

KW - Infliximab

KW - Leflunomide

KW - Methotrexate

KW - Rheumatoid arthritis

KW - Rituximab

KW - Sulfasalazine

KW - Tumor necrosis factor-alpha (TNF-α) inhibitors

UR - http://www.scopus.com/inward/record.url?scp=68949158395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68949158395&partnerID=8YFLogxK

U2 - 10.1517/14656560903071043

DO - 10.1517/14656560903071043

M3 - Review article

VL - 10

SP - 2095

EP - 2106

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 13

ER -